Celgem 200 MG Injection (Gemcitabine)

Product Name: Celgem 200 mg Injection
Generic Name: Gemcitabine 200 mg

Description:
Celgem 200 mg Injection contains Gemcitabine, an antimetabolite chemotherapy drug used to treat various cancers, including non-small cell lung cancer, pancreatic cancer, breast cancer, ovarian cancer, and bladder cancer. It works by interfering with DNA synthesis, preventing cancer cells from growing and dividing.

Key Details:
✅ Strength: Celgem 200 MG Injection 200 mg per vial
✅ Form: Injectable solution (administered intravenously)
✅ Indications:

• Non-small cell lung cancer

• Pancreatic cancer

• Breast cancer

• Ovarian cancer

• Bladder cancer

✅ Mechanism of Action: Celgem 200 MG Injection Inhibits DNA replication in cancer cells, causing cell death.

Usage Instructions:

• Administered by a healthcare professional in a hospital or clinic setting.

• Dosage and schedule depend on the type of cancer and patient’s condition.

• Usually given as an intravenous infusion over 30 minutes.

Common Side Effects:

• Nausea, vomiting

• Fatigue

• Fever, flu-like symptoms

• Low blood cell counts (anemia, leukopenia, thrombocytopenia)

• Rash or skin reactions

Serious Warnings (seek medical help):

• Shortness of breath or chest pain

• Severe bone marrow suppression (very low blood counts)

• Liver or kidney problems

Important Notes:

• Blood tests are required regularly to monitor blood counts and organ function.

• Inform your doctor about all medications and health conditions.

• Avoid pregnancy during treatment (harmful to an unborn baby).

Storage Instructions:

• Celgem 200 MG Injection Store vials below 25°C (77°F).

• Protect from light; keep the vial in the outer carton until ready to use.

• Do not freeze.

• Once reconstituted, the solution should be used promptly or stored as per healthcare facility guidelines.

Precautions and Warnings:
⚠ Pregnancy & Breastfeeding:

• Not recommended during pregnancy; may harm the unborn baby.

• Avoid breastfeeding while on treatment and for a recommended period after the last dose.

⚠ Immune System Effects:

• Celgem 200 MG Injection can weaken the immune system, increasing infection risk.

• Avoid close contact with people who have contagious infections.

⚠ Kidney & Liver Monitoring:

• Regular assessment of kidney and liver function is necessary during treatment.

• Inform your doctor immediately if you notice yellowing of the skin or eyes, dark urine, or swelling.

Drug Interactions:

• Other chemotherapy agents: Celgem 200 MG Injection Combining Gemcitabine with other anticancer drugs may increase side effects or require dose adjustments.

• Radiation therapy: Using Gemcitabine with or soon after radiation may increase the risk of tissue injury (radiation recall).

• Herbal products or supplements: Always inform your doctor if you are using herbal remedies or over-the-counter supplements, as some may affect Gemcitabine’s action.

Patient Advice:
✅ Before starting treatment:

• Discuss your full medical history, especially if you have liver, kidney, or heart problems.

• Share any history of low blood cell counts or prior chemotherapy.

• Discuss fertility concerns, as Gemcitabine can affect fertility in both men and women.

✅ During treatment:

• Stay well hydrated unless otherwise directed by your doctor.

• Avoid alcohol, as it can stress the liver.

• Report unusual symptoms such as bleeding, bruising, fever, chills, or severe fatigue immediately.

✅ After treatment:

• Attend all follow-up appointments and blood tests as scheduled.

• Use effective contraception during and for a period after treatment, as advised by your doctor.

Additional Important Information:

• Brand names and availability may vary by country; always confirm with your pharmacist or supplier.

• Pricing and insurance coverage can differ depending on the healthcare system and provider — check with your insurance or hospital billing office if needed.

• Supportive care (such as anti-nausea medications, antibiotics if needed, and blood transfusions) may be part of the overall treatment plan.